Wednesday, 8 July 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 08 July 2026
News

Another drug leaving Australia

Posted 8 July 2026 AM

Indivior’s opioid dependence drug Sublocade will be removed from the Australian market at the end of the year, leaving Camurus’ Buvidal as the only subsidised long-acting injectable buprenorphine.

The move comes just seven years after the Sublocade was first registered in Australia for treatment of opioid dependence, within a framework of medical, social and psychological treatment

To see the whole article, please login

Popular

Revenue soars 25% on broad listing
Who's been named GM... again?
Blockbusters stuck in PBS limbo
Extra leave coming to pharma?
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (24)

Access & Reimbursement (1)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home